The Effect of NAC on Lung Function and CT Mucus Score
Key facts
- Who runs it
- University of California, San Francisco
- Where
- San Francisco, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 4
- People taking part
- 4 people enrolled
- Started
- 20 Feb 2019
- Ended
- 21 Feb 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- n-acetylcystine + albuterol
- 0.9% saline + albuterol
- Record updated
- 11 June 2026
- Why it stopped
- The study was terminated due to COVID restrictions and funding challenges. The study was then simplified and redesigned as the TEAM study (NCT06152653).
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (19)Hide the full registry criteria
Who can take part
- Male or female between the ages of 18 and 80 years of age at Visit 1
- Written informed consent obtained from subject and ability for subject to comply with the requirements of the study
- Able to perform reproducible spirometry according to American Thoracic Society (ATS) criteria
- Physiological evidence of airflow obstruction (FEV1 bronchodilator reversibility of ≥ 12% or hyperreactivity to methacholine reflected by a methacholine provocative concentration that results in a 20% fall in FEV1(PC20) ≤ 16 mg/mL)
- Clinical history of asthma per patient report or medical record
- Pre-bronchodilator FEV1 > 35% predicted
- Post-bronchodilator FEV1 > 40% but < 90% predicted
- Asthma requiring treatment with inhaled corticosteroids (ICS) for 3 months or greater
- CT mucus score ≥ 5
- Ability to tolerate study drug reflected by a post-treatment FEV1 ≥ 80% of pre- treatment, pre-bronchodilator FEV1
Who cannot take part
- Adherence to study drug ≤ 70% after first treatment period
- Current participation in an investigational drug trial
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data
- Other chronic pulmonary disorders, including (but not limited to) cystic fibrosis, chronic obstructive pulmonary disease, chronic bronchitis, vocal cord dysfunction (that is the sole cause of respiratory symptoms and at the PI's discretion), severe scoliosis or chest wall deformities that affect lung function, or congenital disorders of the lungs or airways
- History of allergy or intolerance to study drug
- Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study
- Smoking of tobacco or other recreational inhalants in last year and/or >10 pack-year smoking history
- Unwillingness to follow study procedures
- Any other criteria that places the subject at unnecessary risk according to the judgment of the Principal Investigator
Where in United States
- UCSF Airway Clinical Research CenterSan Francisco, United States
About the trial
What the trial wants to find out
This study evaluates 20% n-acetylcysteine (NAC) in the treatment of moderate-to-severe asthma that is complicated by mucus in the airway, as determined by CT imaging. The study is a crossover design, which means that half the study participants will get 20% NAC in the first 14-day treatment period and placebo in the next 14-day treatment period; and the other half will get placebo in the first 14-day treatment period and 20% NAC in the next 14-day treatment period.
The 2 groups in the trial
- 20% n-acetylcystine (NAC)Treatment being tested
Participants will self-administer nebulized 20% NAC (3 mL) and 2.5 mg albuterol inhalation solution (0.5 mL) 3 times per day for 14 days.
Treatment: n-acetylcystine + albuterol
- 0.9% salinePlacebo, for comparison
Participants will self-administer nebulized 0.9% saline (3 mL) and 2.5 mg albuterol inhalation solution (0.5 mL) 3 times per day for 14 days.
Treatment: 0.9% saline + albuterol
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 11 June 2026